Role of Bordetella bronchiseptica in the atrophic rhinitis challenge model used for Rhiniseng® pre-clinical efficacy testing

Home Knowledge Role of Bordetella bronchiseptica in the atrophic rhinitis challenge model used for Rhiniseng® pre-clinical efficacy testing

Role of Bordetella bronchiseptica in the atrophic rhinitis challenge model used for Rhiniseng® pre-clinical efficacy testing

In this work, the B. bronchiseptica strain to be used for RHINISENG® pre-clinical efficacy testing was characterized in an in vivo model to evaluate its ability to cause atrophic rhinitis lesions by its own.

About this article

Authors

Montané, J.; Monells, M.; Torrents, D.; March, R.; Sitjà, M.; Camprodon, A.

Summary

The toxigenic Bb strain used in the challenge model for RHINISENG® pre-clinical efficacy testing demonstrated its ability to cause atrophic rhinitis lesions by its own, even more than the toxigenic Pm strain used in this study (Figure 1). It has been described that expression of the dermonecrotic toxin by Bb is not necessary for predisposing to infection with toxigenic Pm, therefore the Bb strain selected for vaccine efficacy testing was more pathogenic than required. Moreover, the infection dose of Bb used in RHINISENG® studies was higher than the commonly used for reproducing non-progressive atrophic rhinitis (NPAR), where one milliliter of a suspension of <1•106 CFU/ml is administered.

Related services

Related products

Share this on